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ABSTRACT
Primary  urothelial  carcinoma  of  the  prostate  is  a  rare  clinicopathological  entity  which  as  a  rule  bears  an
unfavourable prognosis. We report a case of a 75 year old male who presented with a history of voiding difficulty.
With a provisional diagnosis of Benign Prostate Hyperplasia both clinically and by needle biopsy a Trans Urethral
Resection was undertaken. Histopathology showed acini lined by malignant transitional epithelial cells with stromal
invasion.  No  primary  in  the  bladder  was  detected  on the  investigation.  A CK  7/  CK  20  copositivity  on
Immunohistochemistry confirmed our diagnosis of Primary Urothelial Carcinoma of Prostate.
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INTRODUCTION
Transitional cell carcinoma of prostate is carcinoma of
urothelial origin. The reported incidence of prostatic
transitional cell carcinoma ranges from 21.8 – 36.7%
depending  mainly  on  the  manner  of examination.
1,2
Urothelial carcinoma of the prostate is rarely primary
and usually represents synchronous or metachronous
spread from carcinoma of bladder and urethra.
3 The
frequency  of  primary urothelial carcinoma, ranges
from 1- 4% of all prostate tumours in adults.
3,4 Most
patients  are  older  with  a  similar  age  distribution  to
urothelial carcinoma of the bladder i.e. 45 to 90 years.
4
The  primary  prostatic  transitional  cell  carcinoma
involves the entire prostatic urethra particularly areas
near the verumontanum, the large prostatic duct and
nearby acini. They presumably arise from urothelium
lining the prostatic urethra and the proximal portion of
prostatic ducts. It has been postulated that these may
develop through a hyperplasia – dysplasia sequence,
possibly  from  reserve  cells  within  the  urothelium.
5
Stephen et al
6 also suggests that tumour originating in
the  prostate  may  be  the  result  of  malignant
transformation  of  prostatic urothelium. On  the  other
hand  secondary  prostatic  transitional  cell  carcinoma
mainly involves the bladder neck or posterior prostatic
tissue and results from the direct pagetoid spread of
urothelial  carcinoma  in  situ  or a  direct  pathologic
invasion of  bladder  urothelial  carcinoma. However
whether  primary  or  secondary  transitional  cell
carcinoma  of  prostate  is  believed  to  have  a  poor
prognosis.
7
CASE REPORT
A  75yr  old  male  patient  presented  with  a  3  month
history of voiding difficulty, symptoms of nocturia and
very few episodes of dysuria. This was not associated
with  significant  anorexia  or  weight  loss. No  other
positive  history  was  elicited. Serum  PSA done  was
within  normal  limits. Ultrasonography  revealed
prostatic enlargement without any nodules.
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Initial prostatic biopsy with a provisional diagnosis of
Benign  Prostatic  Hyperplasia reported  focal  acini
showing hyperplasia with low grade PIN changes.
The  patient  was  followed  with Trans  Urethral
resection  of  prostate which  revealed  prostatic  acini
with  adenomatous  hyperplasia  and  a  focus  of  ducts
lined  by  malignant  transitional  epithelial  cells  with
mitotic  figures  and  areas  of  necrosis  and  stromal
invasion. – suggesting Transitional cell carcinoma of
prostate.
Fig 1: Urothelial Carcinoma Prostate 40x
Fig 2: High grade cytological features (40x)
Fig 3: Cytokeratin 7 positivity (40x)
The urinary bladder was evaluated with clinical and
ultrasonography  to  rule  out  secondary  TCC  prostate
from a bladder primary carcinoma. This turned out to
be negative.  Immunohistochemisty with CytoKeratin
7  (CK  7)  and  Cytokeratin  20  (CK 20)  was  positive
while Prostate Specific Antigen (PSA) was negative
which confirmed our diagnosis.
DISCUSSION
Prostate cancer is one of the most common cancers in
men. Prostatic cancer occurs microscopically in up to
50% men by the age of 50 and almost all men aged 80
years showed some microscopic evidence of prostate
cancer.
8 Besides  the  garden  variety  of  prostatic
adenocarcinoma many variants and a wide histological
spectrum  have been  described.  These  include
mucinous carcinoma, neuroendocrine carcinoma,
sarcomatoid  carcinoma,  squamous  cell  carcinoma,
urothelial carcinoma etc.
3
Primary urothelial carcinoma of prostate is rare with
an  incidence  ranging  from  1-4%
3,4 and  arises  either
from prostatic urethra or from the urothelial lining of
the larger periurethral prostatic ducts.
9 Patients usually
present  with  symptoms  of  haematuria,  urinary
obstruction or prostatitis as was seen in our case.
3,10
Wadhwa et al
11 describes an atypical case presenting
as bleeding per rectum due to a rectal ulcer. Digital
rectal examination is abnormal in the majorityof cases
but is rarely the presenting sign.
10 Clinically urothelial
carcinoma  of  prostate  may  be  mistaken  for  nodular
hyperplasia  or  prostatitis  which  was  the  provisional
diagnosis  in  our  case  too.
3 Serum  prostate  specific
antigen  (PSA)  which  is  the  cornerstone  in  the
diagnosis of prostatic adenocarcinoma is not elevated
in  primary  urothelial  carcinoma  of  prostate  (<  4
ng/dl).
3 Radiological  findings  can  overlap  and play
limited role in the diagnosis of unusual neoplasms of
prostate including urothelial carcinomas.
12 Most cases
are diagnosed by TUR or less often by needle biopsy.
13
TURP is preferred due to more false negative reports
with needle  biopsy  as  seen  in  our  case  as  well.
However, in all suspected cases of primary urothelial
prostate  cancer  the  possibility  of  secondary
involvement  from  an  apparent  or  occult  bladder
primary must be excluded. This may require random
biopsies of urinary bladder mucosa.
14
Histologically  the  diagnostic  criteria  for  primary
prostatic urothelial carcinoma are identical to those for
urothelial  cancer  of  the  bladder;  most  cancers  are
moderately  or  poorly  differentiated  and  usually
associated  with  prominent  chronic  inflammation.214
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Squamous metaplasia is rare.
3 They may be seen to
spread by invasion of prostatic stroma initially. Local
spread  beyond  prostate  gland  as  well  as  metastasis
may occur.
10 Distinguishing urothelial carcinoma from
prostatic  adeno  carcinoma  is  clinically  important
because  of  the  oestrogen  unresponsiveness  of  the
former.
3 Prostatic  adenocarcinoma  may  respond  to
hormonal therapy and cystoprostatectomy may not be
needed.  Diagnosis  also  determines  the  stage  for
prognostication.
15 Urothelial Carcinoma is  usually
distinguished  from  poorly-differentiated  Prostatic
AdenoCarcinoma by  its  histopathological
characteristics (Fig 1) including the presence of solid
nests  of  cells  associated  with  dense  or  abundant
cytoplasm and striking nuclear pleomorphism, with the
absence or rarity of glandular lumina. The serum free
PSA  level  is  a  main  marker  for  prostate
adenocarcinoma screening
15 .In  difficult  cases  IHC
may be mandatory. The sensitivity and specificity of
PSA are high in prostate cancer, at 100% sensitivity.
In poorly-differentiated prostate cancer and PAC, the
expression levels of PSA may reach 85–95%. PSA is
the  oldest  and  most  commonly  used
immunohistochemical  marker  to identify  cancers  of
prostatic  origin.
16 CK7  and  CK20  are  also  useful
markers to distinguish PAC from UC. Bassily et al
17
studied the expression of CK7 and CK20 in PAC and
UC, and estimated their usefulness for distinguishing
between the two tumors. In the prostatic and metastatic
tumors, neither was positive for the markers. However,
61%  of  the  UC  cases  were  positive  for  CK7  and
CK20.
CONCLUSION
Primary urothelial carcinoma is a rare type of prostatic
carcinoma  which  as  a  rule  bears  an  unfavourable
prognosis. As a primary tumor it makes only 1-4 % of
tumors  of  the  prostate. It  originates  in  the  poorly
differentiated  reservoir  cells  of  the  prostatic
periurethral  ductus  which  explains  why  diagnosis  is
most often obtained in advanced stages thus limiting
its management to radical surgery. Its distinction from
prostatic  adenocarcinoma  is  pertinent  for  both
treatment and prognostication. Thus Transitional Cell
Carcinoma should  be  considered  as  a  differential
diagnosis  in  cases  with  obstructive  symptoms  and
normal PSA.
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